MS news

About MS

people-219985_640

Long-term Lemtrada Treatment Benefits Demonstrated in Extension Study

Source Multiple Sclerosis News Today: A five-year study demonstrated that Sanofi-Genzyme’s Lemtrada (alemtuzumab) provides long-term benefits for relapsing-remitting multiple sclerosis patients, reducing relapse rates and preventing the progression of the disease. Importantly, most patients required only the standard two-phase treatment course. Few needed additional courses because of relapse or new brain lesions.  Read on.

Long-term Lemtrada Treatment Benefits Demonstrated in Extension Study Read More »

upset-534103_640

Got cog fog?

Source MS Trust: Cognition and cognitive symptoms About half of all people with multiple sclerosis have some degree of problem at some time with aspects of thinking – memory, attention span, planning, decision making, understanding or concentration

Got cog fog? Read More »

Scroll to Top